Chemotherapy plus pentamidine for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of two drugs—a standard chemotherapy called FOLFIRINOX and an investigational drug called pentamidine—in people with advanced pancreatic cancer. The goal is to see if this combination is safe and effective, and it may slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have pancreatic cancer that is advanced (spread) or cannot be removed by surgery.
- You have at least one tumor that can be measured and are willing to have a biopsy (tumor sample) before treatment and after the 8th round.
- You are in good enough health to care for yourself and are not bedridden.
- Your blood counts, liver, and kidney function are within acceptable limits for this study.
- You have not had chemotherapy for metastatic pancreatic cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This trial tests whether adding the malaria drug mefloquine to standard chemotherapy can help treat pancreatic cancer. It may make the chemotherapy more effective for people whose cancer cannot be removed by surgery or has spread.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This study tests a combination of three drugs—two pills and one infusion—for people with advanced pancreatic cancer who have already tried one or more treatments. It may help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.